Precision Neuroscience Raises $250M for Brain Interface Tech

The race to bridge the human brain with digital systems is intensifying, with Precision Neuroscience emerging as a significant contender. The company has successfully closed an oversubscribed $250 million Series D funding round, propelling its total capital raised to $430 million. This substantial investment, which reportedly values the company at just over $1 billion, underscores the growing investor confidence in advanced neurotechnology.

The latest funding was co-led by prominent investment firms Pershing Square Inc. and the Ackman Oxman Institute, alongside a leading life sciences investment fund. Significant participation also came from Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures, and JSL Health Capital. This broad base of support highlights a diverse group of investors recognizing the transformative potential of brain-computer interfaces (BCIs).

Precision Neuroscience is developing its innovative Layer 7™ Cortical Interface, a surface-level BCI designed for minimally invasive implantation. Unlike traditional methods requiring a craniotomy, the Layer 7 system utilizes a film thinner than a human hair, equipped with 1,024 microelectrodes. This design allows for high-resolution neural signal recording directly from the brain's surface without penetrating tissue, and crucially, is engineered for safe removal. The device has already achieved FDA 510(k) clearance for up to 30 days of clinical use, and recent demonstrations showcased high-resolution recording across 4,096 electrodes with real-time decoding of intended movement.

The company's clinical progress is marked by strategic partnerships and research collaborations. A notable alliance with Medtronic aims to integrate Layer 7 with the established StealthStation surgical navigation system, marking a key step in bridging BCI startups with major medical device manufacturers. Furthermore, Precision Neuroscience is actively engaged with leading academic institutions, including Johns Hopkins University and the University of Pennsylvania’s Perelman School of Medicine, where its technology is being used to map the human motor cortex. The addition of Dr. John Donoghue, a pioneer in BCI and founder of BrainGate, as a scientific advisor further bolsters the company's scientific credibility.

This funding round arrives amidst a surge of capital flowing into the BCI sector. Competitors like Neuralink, which raised $650 million, and Synchron, with its $200 million Series D, are also advancing their respective technologies. Science Corporation, focused on vision restoration, secured $230 million, while Sam Altman's Merge Labs garnered $252 million for its non-invasive approach. The market is clearly demonstrating a strong appetite for diverse BCI solutions, from invasive implants to less intrusive methods.

The $250 million infusion will be instrumental in expanding Precision Neuroscience's clinical programs, advancing the Layer 7 interface through further FDA regulatory stages, and building out the necessary commercialization infrastructure. With over 100 patient procedures completed across 18 major medical institutions—representing the most extensive clinical footprint in the BCI field—and an in-house MEMS manufacturing facility in Texas, the company is strategically positioning itself for scalable deployment. CEO Michael Mager emphasized that future BCI success will hinge on a combination of technology, clinical networks, regulatory standing, and manufacturing capabilities, with safety as a core tenet.